KRYS Wutah bathi saben saham ing taun iki Krystal Biotech, Inc.

Lambang korporat lan logo Krystal Biotech, Inc. (KRYS)

The annual earnings per share trajectory demonstrates revenue dynamics, where 12.00 captures the current value of the indicator. Krystal Biotech, Inc. (KRYS) possesses a unique gene therapy platform that ensures pricing power through its drug Vyjuvek. The explosive commercial success of the skin-correcting genetic gel is complemented by strategic partnerships with leading global clinics and research centers.

Wutah bathi saben saham ing taun lumaku Krystal Biotech Inc (KRYS): kanggo periode 04.07.2022 - 16.11.2026

Rincian analitis lan laporan data perusahaan Krystal Biotech Inc (KRYS)

- kuotasi saiki lan rata-rata prakiraan nilai:
Ringkesan analisis perusahaan:Krystal Corp - KRYS
Produk mawa merek Krystal Biotech

Positive earnings per share dynamics signal to institutional investors the high efficiency of Krystal Biotech, Inc. (KRYS) organic scaling following the commercialization of its core drug. By analyzing the EPS YoY percentage shift on GURU.Markets, you assess the real return on capital accounting for operational logistics costs, which confirms the fundamental resilience of the business in the absence of external mergers.